| MORPHOSYS AG O.N. | 109.00 / -2.90% |
| Date/Time | 08/07 / 08:09 |
| Chg. / Chg.(%) | -3.25 / -2.90% |
| Bid | 107.00 / 200 |
| Ask | 108.00 / 200 |
| Open | 109.00 |
| Previous Close | 112.25 |
| High | 109.00 |
| Low | 109.00 |
| Volume [EUR] | 0.00 |
| Volume [Units] | 0 |
| Price fixings | 1 |
| ISIN | DE0006632003 |
| Security | MOR |
| Exchange | Hamburg |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| TradeGate | 110.150 |  |
1,783 |
| gettex | 110.100 | |
50 |
| Lang & Schwa.. | 108.300 | |
|
| Xetra | 107.00 |  |
237,193 |
| London Inter.. | 106.35 | |
80,207 |
| Cboe Europe .. | 107.15 | |
59,649 |
| Nasdaq Other.. | 125.9600 | |
50,900 |
| Turquoise | 107.15 | |
22,486 |
| Cboe Europe .. | 107.10 | |
19,706 |
| Stuttgart | 106.250 | |
1,968 |
| Frankfurt | 106.5000 | |
618 |
| Berlin | 107.00 | |
80 |
| München | 105.05 | |
76 |
| Vienna Globa.. | 107.70 | |
16 |
| Hannover | 110.00 | |
1 |
| Hamburg | 109.00 | |
0 |
| Düsseldorf | 110.20 |  |
0 |
| SIX Swiss Ex.. | 102.00 | |
|
| EUREX | Options | ||
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
01/31/2019 / 13:36 - GlobeNewswire
Real-time